Загрузка...
Introducing Vernakalant into Clinical Practice
Vernakalant is an antiarrhythmic drug licensed for the pharmacological cardioversion of recent onset AF. Randomised clinical trials, backed up by real-world experience, have confirmed its efficacy at restoring sinus rhythm. Vernakalant can be administered simply with a short time to action, facilita...
Сохранить в:
| Опубликовано в: : | Arrhythm Electrophysiol Rev |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Radcliffe Cardiology
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6434499/ https://ncbi.nlm.nih.gov/pubmed/30918671 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15420/aer.2018.71.2 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|